Dry Age Related Macular Degeneration Clinical Trial
Official title:
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01674829 -
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
|
Phase 1/Phase 2 | |
| Completed |
NCT00751361 -
Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial
|
Phase 4 | |
| Enrolling by invitation |
NCT03305029 -
The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD
|
Phase 1 | |
| Completed |
NCT01344993 -
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00804102 -
Transcorneal Electrical Stimulation Therapy for Retinal Disease
|
N/A | |
| Completed |
NCT00429936 -
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
|
Phase 2 |